Literature DB >> 10465711

Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores.

T A Bayer1, P Jäkälä, T Hartmann, L Havas, C McLean, J G Culvenor, Q X Li, C L Masters, P Falkai, K Beyreuther.   

Abstract

A growing body of evidence suggests that the non-Abeta component of Alzheimer's disease amyloid precursor protein (NACP) or alpha-synuclein contributes to the neurodegenerative processes in Alzheimer's disease (AD), Parkinson's disease (PD) and dementia with Lewy bodies (DLB). In the present study antisera to the N terminus and the NAC domain of the alpha-synuclein protein were employed to elucidate the expression pattern in brains of patients with AD, PD, DLB and control specimen. Alpha-synuclein exhibited an overall punctuate expression profile compatible with a synaptic function. Interestingly, while Lewy bodies were strongly immunoreactive, none of the alpha-synuclein antisera revealed staining in mature beta-amyloid plaques in AD. These observations suggest that alpha-synuclein does not contribute to late neurodegenerative processes in AD brains.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10465711     DOI: 10.1016/s0304-3940(99)00311-0

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  23 in total

1.  The role of NAC in amyloidogenesis in Alzheimer's disease.

Authors:  M Hashimoto; T Takenouchi; M Mallory; E Masliah; A Takeda
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

2.  Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model.

Authors:  P J Kahle; M Neumann; L Ozmen; V Müller; S Odoy; N Okamoto; H Jacobsen; T Iwatsubo; J Q Trojanowski; H Takahashi; K Wakabayashi; N Bogdanovic; P Riederer; H A Kretzschmar; C Haass
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

3.  Specific antibodies to soluble alpha-synuclein conformations in intravenous immunoglobulin preparations.

Authors:  L M Patrias; A C Klaver; M P Coffey; D A Loeffler
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

4.  Insoluble alpha-synuclein in Alzheimer's disease without Lewy body formation.

Authors:  Melissa Broe; Claire E Shepherd; David M A Mann; Elizabeth A Milward; Wei-Ping Gai; Emma Thiel; Glenda M Halliday
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

5.  LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress.

Authors:  Ha Nam Nguyen; Blake Byers; Branden Cord; Aleksandr Shcheglovitov; James Byrne; Prachi Gujar; Kehkooi Kee; Birgitt Schüle; Ricardo E Dolmetsch; William Langston; Theo D Palmer; Renee Reijo Pera
Journal:  Cell Stem Cell       Date:  2011-03-04       Impact factor: 24.633

6.  Multiplication of the alpha-synuclein gene is not a common disease mechanism in Lewy body disease.

Authors:  Paul J Lockhart; Jennifer Kachergus; Sarah Lincoln; Mary Hulihan; Gina Bisceglio; Natalie Thomas; Dennis Dickson; Matthew J Farrer
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 7.  Genetic variability in SNCA and Parkinson's disease.

Authors:  Lasse Pihlstrøm; Mathias Toft
Journal:  Neurogenetics       Date:  2011-07-29       Impact factor: 2.660

8.  Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations.

Authors:  Wenxue Li; Neva West; Emanuela Colla; Olga Pletnikova; Juan C Troncoso; Laura Marsh; Ted M Dawson; Pekka Jäkälä; Tobias Hartmann; Donald L Price; Michael K Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-31       Impact factor: 11.205

Review 9.  Lewy body pathology in Alzheimer's disease.

Authors:  P T Kotzbauer; J Q Trojanowsk; V M Lee
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

Review 10.  Neurobiology of alpha-synuclein.

Authors:  Kostas Vekrellis; Hardy J Rideout; Leonidas Stefanis
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.